U.S. Markets close in 1 hr 17 mins

Genentech's first scientist now focused on Bay Area's latest biotech IPO

Ron Leuty
American City Business Journals
Genentech's first scientist now focused on Bay Area's latest biotech IPO

Dave Goeddel helped build Genentech and Tularik and played a key role in building NGM's portfolio of drugs, including an experimental treatment for nonalcoholic steatohepatitis, or NASH.